Speculators have built a record short position in the Chicago Board of Trade (CBOT) soybean meal contracts, with net shorts reaching 88,971 as of December 17. This reflects strong US soybean crushing ...

What’s going on here? Coforge seized attention by sealing a massive $1.56 billion partnership with US-based Sabre Corp, boosting its share value by 10%. What does this mean? This landmark ...

Lower than expected forecasts for 2025 revenue and profit due to tough competition and reduced cloud spending impact Datadog's market performance. Datadog's shares took a hit, dropping 10% in ...

Hundreds of thousands of Polish homeowners took out Swiss franc mortgages in the early to mid-2000s, attracted by lower interest rates. But the Swiss franc's appreciation against the zloty and recent ...

What’s going on here? Whale Rock Capital Management plans to reopen its flagship tech-focused fund early next year, aiming to attract $200 to $300 million following a remarkable 51% surge this year.

What’s going on here? Virtu Financial is eyeing China's market-making sector, aiming to seize trading opportunities in the country's burgeoning ETF market. China is mulling over opening its $520 ...

The mega-merger highlights how giants from snacks to health are joining forces to keep up with shifting trends and fierce competition in the US consumer goods market. This move signals another wave of ...

A review found staff hesitate to raise red flags, prompting ANZ to overhaul risk practices after a record penalty and regulatory action. ANZ Group is shaking up how it manages risk after an ...

What’s going on here? Volatility-linked funds have recently sold off a hefty $150 billion in US stocks, sparking significant market downturns. Yet, recent signs hint at a potential rebound. The sharp ...

Investors embraced the Fed's gentler approach with rate cut bets and a weaker dollar, setting the stage for market rallies. The Federal Reserve just cut rates by a quarter point and hinted at a ...

Amsterdam-based Palinuro Capital promises to shake up the hedge fund scene with its ambitious goal of outperforming the market during turbulent times. Founded by Alfonso Peccatiello, who doubles as ...

What’s going on here? In a significant development, Shionogi & Co's COVID-19 drug, ensitrelvir, did not meet its primary objectives in a crucial global Phase 3 trial, casting doubt on its efficacy and ...